Critical assessment of angiogenesis inhibitors in clinical trials.
Eskens
Ferry
F
Erasmus Medical Center, Rotterdam, The Netherlands.
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D004727:Endothelium / Q000166:cytology; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy; D009389:Neovascularization, Pathologic; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D013267:Stilbenes / Q000494:pharmacology; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D013267:Stilbenes; D000068258:Bevacizumab; D011505:Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; C058728:fosbretabulin